

BIOANALYTICAL SYSTEMS INC
Form 8-K
March 18, 2013

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 14, 2013

BIOANALYTICAL SYSTEMS, INC.
(Exact name of registrant as specified in its charter)

Indiana
(State or other jurisdiction of incorporation or
organization)

0-23357
(Commission File
Number)

35-1345024
(I.R.S. Employer Identification
No.)

2701 KENT AVENUE

WEST LAFAYETTE, INDIANA 47906-1382
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (765) 463-4527

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act(17CFR240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act(17CFR240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act(17CFR240.13e-4(c))

Item 5.07. Submission of Matters to a Vote of Security Holders

On March 14, 2013, Bioanalytical Systems Inc. (the “Company”) held its annual meeting of shareholders at its corporate offices located at 2701 Kent Avenue, West Lafayette, IN 47906. A total of 5,638,186 shares of the Company’s common stock outstanding and entitled to vote were present at the meeting in person or by proxy. The following is a summary of the matters voted on at the meeting.

a.) Two Class I members of the Board of Directors were elected to serve three-year terms ending in 2016 with the following votes cast:

Nominee	For	Withheld	Broker Non-Vote
Larry S. Boulet	3,085,183	193,096	2,359,907
A. Charlene Sullivan, Ph.D.	3,028,707	249,572	2,359,907

b.) The appointment of Crowe Horwath LLP as our independent registered public accountants for fiscal 2013 was ratified by the following shareholder vote:

For:	3,963,099
Against:	1,575,634
Abstain:	99,453

c.) By the following vote, the shareholders approved an advisory vote on compensation paid to named executive officers:

For:	3,025,362
Against:	184,042
Abstain:	68,875

Broker
Non-Vote: 2,359,907

d.) By the following vote, the shareholders voted, on an advisory basis, to hold future advisory votes on executive compensation every three years:

Annually:	694,770
Every 2 years:	45,754
Every 3 years:	2,447,095
Abstain:	90,660
Broker Non-Vote:	2,359,907

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Bioanalytical Systems, Inc.

Date: March 18, 2013 By: /s/ Jacqueline M. Lemke
Jacqueline M. Lemke
President, Chief Executive Officer